Drug Trial Radar · NCT04217473
TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma
Last checked: Nov 19, 2026Latest source record: Aug 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
17
Actual
Start
Feb 26, 2020
Primary completion
Dec 12, 2023
Study completion Jul 23, 2024
Sponsor
- Lead sponsor
- TILT Biotherapeutics Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 3, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, phase 1, first-in-human (FIH), dose-escalation, multicenter, multinational trial evaluating the safety of oncolytic adenovirus TILT-123 as monotherapy and in association with T-cell therapy with TILs in metastatic melanoma patients.
Conditions
- Metastatic Melanoma
Interventions
TILT-123Biological
TNFalpha and IL-2 coding oncolytic adenovirus TILT-123
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with any (serious and non-serious) Adverse Events prior to TIL administration.Time frame: 36 days
- Number of Participants with abnormal laboratory values prior to TIL administration.Time frame: 36 days
- Number of Participants with vital sign abnormalities prior to TIL administration.Time frame: 36 days
- Safety assessed by 12- lead electrocardiograms (ECGs) Adverse Events prior to TIL administration.Time frame: 36 days
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
National Center for Cancer Immune Therapy Herlev Hospital, Copenhagen University
Copenhagen, Denmark
CHU Nantes
Nantes, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.